SCHEDULE 13G
0001569064
XXXXXXXX
LIVE
Common stock, $0.001 par value per share
12/13/2024
0001583648
Palvella Therapeutics, Inc.
697947109
540 Madison Avenue
7th Floor
New York
NY
10022
Rule 13d-1(c)
SUVRETTA CAPITAL MANAGEMENT, LLC
b
DE
0.00
714463.00
0.00
714463.00
714463.00
N
8.6
IA
OO
Averill Master Fund, Ltd.
b
E9
0.00
714463.00
0.00
714463.00
714463.00
N
8.6
CO
Aaron Cowen
b
X1
0.00
714463.00
0.00
714463.00
714463.00
N
8.6
HC
IN
Palvella Therapeutics, Inc.
125 Strafford Avenue, Suite 360, Wayne, Pennsylvania 19087
Suvretta Capital Management, LLC
Averill Master Fund, Ltd.
Aaron Cowen
Suvretta Capital Management, LLC
540 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
Averill Master Fund, Ltd.
c/o Maples Corporate Services Limited
P.O. Box 309
Ugland House
Grand Cayman KY1-1104
Cayman Islands
Aaron Cowen
c/o Suvretta Capital Management, LLC
540 Madison Avenue, 7th Floor
New York, New York 10022
Suvretta Capital Management, LLC - Delaware
Averill Master Fund, Ltd. - Cayman Islands
Aaron Cowen - United States
Y
Suvretta Capital Management, LLC - 714,463
Averill Master Fund, Ltd. - 714,463
Aaron Cowen - 714,463
Suvretta Capital Management, LLC - 8.6%
Averill Master Fund, Ltd. - 8.6%
Aaron Cowen - 8.6%
Suvretta Capital Management, LLC - 0
Averill Master Fund, Ltd. - 0
Aaron Cowen - 0
Suvretta Capital Management, LLC - 714,463
Averill Master Fund, Ltd. - 714,463
Aaron Cowen - 714,463
Suvretta Capital Management, LLC - 0
Averill Master Fund, Ltd. - 0
Aaron Cowen - 0
Suvretta Capital Management, LLC - 714,463
Averill Master Fund, Ltd. - 714,463
Aaron Cowen - 714,463
Y
N
All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common Stock, $0.001 par value per share.
N
Please see Exhibit B attached hereto.
Y
Y
N
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
[Exhibit A - Joint Filing Agreement]
[Exhibit B - Control Person Identification]
SUVRETTA CAPITAL MANAGEMENT, LLC
/s/ Aaron Cowen
12/20/2024
Averill Master Fund, Ltd.
/s/ Aaron Cowen
12/20/2024
Aaron Cowen
/s/ Aaron Cowen
12/20/2024
* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.